Beaufort Securities Reiterates “Speculative Buy” Rating for Amryt Pharma PLC (AMYT)

Amryt Pharma PLC (LON:AMYT)‘s stock had its “speculative buy” rating reaffirmed by research analysts at Beaufort Securities in a research report issued to clients and investors on Tuesday. They presently have a GBX 65 ($0.85) price objective on the stock. Beaufort Securities’ price target would suggest a potential upside of 265.99% from the stock’s previous close.

Separately, Shore Capital dropped their price target on shares of Amryt Pharma PLC from GBX 86 ($1.13) to GBX 70 ($0.92) and set a “house stock” rating for the company in a research report on Thursday, September 21st.

Shares of Amryt Pharma PLC (AMYT) opened at GBX 17.76 ($0.23) on Tuesday. Amryt Pharma PLC has a 12-month low of GBX 13.44 ($0.18) and a 12-month high of GBX 29.50 ($0.39).

WARNING: “Beaufort Securities Reiterates “Speculative Buy” Rating for Amryt Pharma PLC (AMYT)” was published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at

About Amryt Pharma PLC

Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.

Receive News & Ratings for Amryt Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma PLC and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply